Marizyme, Inc. is a medical technology company, which engages in the acquisition, development, and commercialization of therapies that minimize mortality and costs in the acute care space. It offers DuraGraft, a one-time intraoperative vascular graft treatment that improves clinical outcomes by reducing the incidence and complications of graft failure, and Krillase, a patented protease-based therapeutic. The company was founded on March 20, 2007 and is headquartered in Jupiter, FL.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Marizyme Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Marizyme Inc market cap is $132.00.
What is the 52-week high for Marizyme Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Marizyme Inc 52 week high is $0.1195 as of January 21, 2026.
What is the 52-week low for Marizyme Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Marizyme Inc 52 week low is $0.00 as of January 21, 2026.
What is the 50-day moving average of Marizyme Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Marizyme Inc 50-day moving average is $0.00.